Effect of the combination of Astragalus and low molecular weight heparin on immune function in elderly patients with primary nephrotic syndrome
Zhang Yanli
Li Ping
Abstract：Objective To investigate the effect of the combination of astragalus and low molecular weight heparin on immune function in elderly patients with primary nephrotic syndrome. Methods A total of 96 cases of primary nephrotic syndrome were selected from our hospital between March 2015 and April 2016. According to the different treatment methods,patients were divided into the treatment group(n=48)and the control group(n=48). Patients in the control group were treated with routine hormone therapy, and the treatment group was treated with astragalus combined with low molecular weight heparin on the basis of the conventional treatment. The clinical curative effect of the two groups were observed,and changes in the renal function indexes and serum albumin before and after treatment were compared between the two groups. Changes in the levels of immune function indicators and adverse reactions before and after the treatment were compared between the two groups. Results The effective rate of treatment group was 87.50%(42/48),which was significantly higher than the 64.58%(31/48)in the control treatment group,and the difference was statistically significant (P< 0.05). After treatment,the levels of BUN and Scr in the two groups were significantly lower than that in the two groups before treatment. The levels of the two indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment,serum albumin in patients of the two groups were significantly higher than in before treatment,and the level of serum albumin in the observation group was higher than those in the control group(P<0.05). The level of TGF-β,IFN-γand IL-8 in the treatment group was significantly lower than that of the control group. However,the level of IL-13 was the opposite, which was significantly higher than in control group (P < 0.05). There were no significant differences in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The combined astragalus and low molecular weight heparin treatment in elderly patients with primary nephrotic syndrome can effectively decrease BUN and Scr levels and improve renal function. Moreover,this combination treatment can also improve patient immune function and increase clinical efficacy and results in less adverse reactions. Therefore,combined astragalus and low molecular weight heparin therapy is a safe and effective treatment method.
Keywords：AstragalusLow molecular weight heparinPrimary nephrotic syndromeImmunity
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 496-498 )